Quarterly ResultAug 5, 2026, 04:34 PM
Zomedica Q2 Revenue $9.5M, Up 37%; Net Loss Reduced 49%
AI Summary
Zomedica Corp. announced record second-quarter revenue of $9.5 million for Q2 2026, marking a 37% increase year-over-year and extending its streak of consecutive year-over-year revenue growth to 22 quarters. The company significantly reduced its net loss by 49% to $3.8 million and improved cash burn by 38% to $3.4 million, its lowest non-year-end quarterly cash burn on record. Growth was driven by strong performance in its Diagnostics and Therapeutic Devices segments, alongside contributions from the newly formed Development Services segment, while maintaining $44.1 million in liquidity.
Key Highlights
- Q2 2026 revenue increased 37% year-over-year to $9.5 million.
- Net loss for Q2 2026 was $3.8 million, a 49% reduction compared to Q2 2025.
- Operating expenses decreased 20% ($2.6 million) in Q2 2026.
- Cash burn improved 38% to $3.4 million in Q2 2026, a record low non-year-end quarterly burn.
- Diagnostics segment revenue grew 77% year-over-year to $1.4 million.
- Therapeutic Devices segment revenue increased 9% year-over-year to $6.8 million.
- Development Services segment generated $1.4 million in revenue for Q2 2026.
- Zomedica maintained $44.1 million in cash, cash equivalents, and available-for-sale securities as of June 30, 2026.
Price Impact
More from ZOMDF